These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18435534)

  • 1. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.
    Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R
    J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsecond simulations of mdm2 and its complex with p53 yield insight into force field accuracy and conformational dynamics.
    Pantelopulos GA; Mukherjee S; Voelz VA
    Proteins; 2015 Sep; 83(9):1665-76. PubMed ID: 26138282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics.
    Verkhivker GM
    PLoS One; 2012; 7(7):e40897. PubMed ID: 22815859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
    J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
    Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
    J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
    Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
    J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2.
    Bueren-Calabuig JA; Michel J
    PLoS Comput Biol; 2015 Jun; 11(6):e1004282. PubMed ID: 26046940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations.
    Espinoza-Fonseca LM; Trujillo-Ferrara JG
    Biopolymers; 2006 Nov; 83(4):365-73. PubMed ID: 16817233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
    Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
    Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markov models of the apo-MDM2 lid region reveal diffuse yet two-state binding dynamics and receptor poses for computational docking.
    Mukherjee S; Pantelopulos GA; Voelz VA
    Sci Rep; 2016 Aug; 6():31631. PubMed ID: 27538695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
    Chee SM; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
    PLoS One; 2014; 9(8):e104914. PubMed ID: 25115702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry.
    Hernychova L; Man P; Verma C; Nicholson J; Sharma CA; Ruckova E; Teo JY; Ball K; Vojtesek B; Hupp TR
    Proteomics; 2013 Aug; 13(16):2512-25. PubMed ID: 23776060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the Small-Molecule Inhibition of an Anticancer Therapeutic Protein-Protein Interaction Using a Solid-State Nanopore.
    Kwak DK; Chae H; Lee MK; Ha JH; Goyal G; Kim MJ; Kim KB; Chi SW
    Angew Chem Int Ed Engl; 2016 May; 55(19):5713-7. PubMed ID: 27038437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
    Zondlo SC; Lee AE; Zondlo NJ
    Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding induced folding in p53-MDM2 complex.
    Chen HF; Luo R
    J Am Chem Soc; 2007 Mar; 129(10):2930-7. PubMed ID: 17302414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C terminus of p53 binds the N-terminal domain of MDM2.
    Poyurovsky MV; Katz C; Laptenko O; Beckerman R; Lokshin M; Ahn J; Byeon IJ; Gabizon R; Mattia M; Zupnick A; Brown LM; Friedler A; Prives C
    Nat Struct Mol Biol; 2010 Aug; 17(8):982-9. PubMed ID: 20639885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.
    Anil B; Riedinger C; Endicott JA; Noble ME
    Acta Crystallogr D Biol Crystallogr; 2013 Aug; 69(Pt 8):1358-66. PubMed ID: 23897459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins.
    Ha JH; Won EY; Shin JS; Jang M; Ryu KS; Bae KH; Park SG; Park BC; Yoon HS; Chi SW
    J Am Chem Soc; 2011 Feb; 133(5):1244-7. PubMed ID: 21210687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
    McCoy MA; Gesell JJ; Senior MM; Wyss DF
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1645-8. PubMed ID: 12552135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.